NEWS
Cherwell to become AnalytiChem UK
Cherwell (an AnalytiChem company), a microbiology cleanroom solutions expert, is to be renamed AnalytiChem UK from September 2025. This represents the next step in Cherwell’s integration with the AnalytiChem Group, which it joined in January 2024.
This transition is solely a change in name – all other aspects of Cherwell’s long-standing business will remain unchanged. As AnalytiChem UK, Cherwell will continue its 54-year strong legacy supporting its customers in the pharmaceutical manufacturing and related industries to effectively manage their
controlled environments and processes. The name change represents opportunity to grow and deliver an even stronger service and product offering to Cherwell’s customers.
Operating as AnalytiChem UK
from its ISO9001-registered facility in Bicester, where it manufactures its Redipor-branded prepared media products, is the next step in becoming one global company with one mission. All AnalytiChem manufacturing and commercial sites hold a common ethos of delivering quality products and services to support laboratory workflows across a broad range of research and analytical applications in life science and industrial markets. So, greater integration with these sites will ensure shared learning and expertise, plus increased investment to further develop and grow the future AnalytiChem UK product offering, like the recently globalised Redipor range, in line with its customer needs.
Cherwell customers will see no changes other than the company name – location, laboratory and manufacturing processes, quality of products, plus sales and customer service team will all remain the same. “Our name may be changing; but our long-standing Cherwell values and culture will absolutely be maintained and business will very much continue as usual – just with a strengthened ability to collaborate with our sister companies and deliver on the opportunities that this presents for us and our customers,” said Andy Whittard, Managing Director of Cherwell (pictured).
12
Better inclusion of older adults in health research
A joint statement has been signed by over 40 UK health funders and charities, to improve understanding of disease and develop better health interventions. The joint statement sets out a shared commitment to: n actively support the inclusion of older adults in research
n challenge unjustified exclusion, particularly where older adults have complex health conditions
n ensure that research is designed with equity in mind and better reflects the diversity of the UK.
The statement builds on the Chief Medical Officer’s annual report on healthy ageing, which highlighted that older people are routinely underrepresented in clinical trials and research studies. Older people who are living with multiple long-term conditions are particularly underrepresented. Funders are encouraging researchers to design studies that reflect the diversity of the UK population and avoid arbitrary age limits. Including older people more routinely in all stages of health research, from early- stage biomedical research through to clinical trials, is essential. This inclusion will lead to a more integrated understanding
of the complexity of ill-health and how ageing influences disease development and treatment response. The approach will help ensure that future prevention interventions, diagnostics, therapies and care models are effective for those most likely to use them. Researchers are expected to embed diversity and inclusion into the design of studies involving human participants, samples or data. This includes considering characteristics such as age, sex, gender, ethnicity and socio-economic position when designing proposals, recruiting participants and conducting research. Professor Patrick Chinnery, UK Research and Innovation (UKRI) Lead for Health, Ageing and Wellbeing, and Executive Chair of the Medical Research Council, said: “Tackling health inequalities and understanding how to keep people healthier for longer is a key part of UKRI’s strategic theme of securing better health, ageing and wellbeing. I am pleased to sign this statement, ensuring older people are included in research and clinical trials, which will allow us to address important challenges including multiple long-term conditions and poor mental health through advancements in prevention, diagnosis and treatment.
An automated solution for urine specimen aliquoting
Microbiology laboratory and automation firm Copan has launched UriVerse, a state-of-the-art, fully automated system that transforms the pre-analytical handling of urine specimens by automating key manual steps. UriVerse automates critical steps including de-capping, barcode labelling, aliquoting, and re-capping which helps laboratories reduce manual labour and minimise errors. UriVerse can reduce hands-on time and help laboratories handle growing urine volumes with greater efficiency and consistency. UriVerse eliminates manual pipetting and sorting with continuous, random-access loading, cup recognition, and automated aliquoting, labelling and capping, all in one platform.
“Copan continues to pioneer technologies that support the advancement
of laboratory automation,” said Fabrizio Mazzocchi, CEO of Copan Diagnostics. “With UriVerse, we offer an efficient, accurate solution to help laboratories meet rising urine testing demands, particularly in chemistry and toxicology, while reducing variability through the automation of manual pre-analytical tasks.”
SEPTEMBER 2025
WWW.PATHOLOGYINPRACTICE.COM
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84
